Jones J K, Gorkin L, Lian J F, Staffa J A, Fletcher A P
The Degge Group, Arlington VA 22209, USA.
BMJ. 1995 Jul 29;311(7000):293-5. doi: 10.1136/bmj.311.7000.293.
To evaluate the incidence of discontinuation of and changes in treatment after newly prescribed courses of antihypertensive drugs of the four primary therapeutic classes: beta blocker, calcium channel blocker, and angiotensin converting enzyme inhibitor.
A retrospective analysis of patients on an automated database of 1.2 million patients was conducted on visits between 1 October 1992 and 30 September 1993.
General practices in the United Kingdom.
37,643 patients with hypertension receiving a relevant drug in the time period were identified. A new course of treatment in at least one of the four therapeutic classes, defined as a drug not prescribed in the previous four months, was observed in 10,222 patients aged > or = 40 years.
Patients changing to other treatment or discontinuing after initiating a new course of treatment, defined as the absence of a refill prescription for the new drug or another in its category within a six month observation period.
Changes in or discontinuation of treatment were frequently observed, and by month six continuation rates ranged between 40% to 50% for all four classes of drugs.
Low rates of continuation with a newly prescribed antihypertensive drug exist regardless of which drug is prescribed.
评估四类主要抗高血压药物新处方疗程后停药及治疗变化的发生率，这四类药物为β受体阻滞剂、钙通道阻滞剂和血管紧张素转换酶抑制剂。
对1992年10月1日至1993年9月30日期间120万患者自动数据库中的患者进行回顾性分析。
英国的全科医疗。
确定了在此期间接受相关药物治疗的37643例高血压患者。在10222例年龄≥40岁的患者中观察到至少四类治疗药物中的一种新疗程，新疗程定义为前四个月未开过的药物。
开始新疗程后改用其他治疗或停药的患者，定义为在六个月观察期内没有新药或同类药物的续方。
经常观察到治疗变化或停药情况，到第六个月时，所有四类药物的持续治疗率在40%至50%之间。
无论开哪种药物，新处方抗高血压药物的持续治疗率都较低。
